Publications

Original papers

  1. Anzenbacherová E., Anzenbacher P., Macek K., Květina J.:
    Determination of enzyme angiotensin convertase inhibitors based on enzymatic reaction followed by HPLC.
    J. Pharm. Biomed. Analysis 24(5-6): 1151-1156 (2001) (1,78)
  2. Souček P., Anzenbacher P., Zuber R., Anzenbacherová E., Guengerich F.P.:
    Cloning, expression and characterization of cytochrome P450 3A in minipig.
    Toxicology 164, (1-3), 146 (2001) (1,75)
  3. Anzenbacher P., Hudeček J.:
    Differences in flexibility of active sites of cytochromes P450 probed by resonance Raman and UV/VIS absorption spectroscopy.
    J. Inorg. Biochem. 87, 209-213 (2001) (1,73)
  4. Lange R., Bec N., Anzenbacher P., Gorren A..F.:
    Use of high pressure to study elementary steps in P450 and nitric oxide synthase.
    J. Inorg. Biochem. 87, 191-195 (2001) (1,73)
  5. Souček P., Zuber R., Anzenbacherová E., Anzenbacher P.:
    Minipig cytochrome P450 enzymes have similar properties to human analogs.
    BMC Pharmacology 1, 11-15 (2001)
  6. Anzenbacher P., Anzenbacherová E., Zuber R., Souček P., Guengerich F.P.:
    Pig and minipig cytochromes P450.
    Drug Metab. Disposition 30, 100 (2002) (2,99)
  7. Zuber R., Modrianský M., Dvořák Z., Rohovský P., Ulrichová J., Šimánek V., Anzenbacher P.:
    Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities.
    Phytotherapy Res. 16, 632-638 (2002) (0,60)
  8. Bancel F., Hui Bon Hoa G., Anzenbacher P., Balny C., Lange R.: High pressure:
    A new tool to study P450 structure and function.
    Meth. Enzymol. 357, 145-157 (2002) (1,79)
  9. Štětinová V., Smetanová L., Grossmann V., Anzenbacher P.:
    In vitro assessment of the antioxidant activity of melatonin and related indole derivatives.
    Gen. Physiol. Biophys. 21, 153-162 (2002) (0,93)
  10. Anzenbacherová E., Filipová K., Nobilis M., Anzenbacher P.:
    Selective determination of famotidine in human plasma by high performance liquid chromatography in alkaline media with solid phase extraction.
    J. Separ. Sci. 26, 722-726 (2003) (2.018)
  11. Kousalova L, Anzenbacherova E, Baranova J, et al.:
    Presence of cytochrome P450 enzymes in human CD34(+) haematopoietic progenitor cells Gen.
    Physiol. Biophys. 23, 251-257 (2004) (0.694)
  12. Mičuda S., Mundlová L., Anzenbacherová E., Anzenbacher P., Chládek J., Fuksa L. Martínková J.:
    Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions.
    Eur J Clin Pharmacol. 60, 583-589 (2004)(1.972)
  13. Anzenbacherová E., Baranová J., Zuber R., Pěchová A., Anzenbacher P., Souček P., Martínková J.:
    Model systems based on experimental animals for studies on drug metabolism in man: Minipig cytochromes P450 CYP3A29 and 2E1.
    Basic Clin. Pharmacol. Toxicol. 96, 244-245 (2005) (1.342)
  14. Baranová J., Anzenbacherova E., Anzenbacher P., Souček P.:
    Minipig cytochrome P4502E1: Comparison with human enzyme.
    Drug Metab. Disposition 33, 862-865 (2005) (3.836)
  15. Anzenbacherová E., Hudeček J., Murgida D, Hildebrandt P., Marchal S., Lange R., Anzenbacher P.:
    Active sites of two orthologous cytochromes P450 2E1: Differences revealed by spectroscopic methods.
    Biochem. Biophys. Res. Commun. 338, 477-482 (2005) (2.904)
  16. Souček P., Anzenbacher P., Skoumalova I., Dvorak M.:
    Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells.
    Stem Cells 23(9), 1417-1422 (2005)
  17. Zídek Z., Anzenbacher P., Anzenbacherova E., Buchar., Kmoničková E., Potměšil P., Holý A.:
    In vivo effects of antiviral acyclic nucleoside phosphonate 9 [2-(phosphonomethoxy)ethyl]adenine (adefovir) on cytochrome P450 system of rat microsomes. J Biomed Sci. Jan 14;1-7 (2006)
  18. Nekvindová J., Mašek V., Veinlichová A., Anzenbacherová E, Anzenbacher P., Zídek Z., Holý A.:
    Inhibition of human liver microsomal cytochrome activities by adefovir and tenofovir.
    Xenobiotica, 36(12):1165-77 (2006)
  19. Matal J., Orság J., Nekvindová J., Anzenbacherová E., Veinlichová A., Anzenbacher P., Zídek Z., Holý A:
    Experimental approaches to studies on drug metabolism and drug interaction in man: interaction of acyclic nucleoside phosphonates with human liver cytochromes P450 and flavin-containing monooxygenase 3.
    Neuroendocrinol. Lett. 27, Suppl.2, 27-30 (2006)
  20. Hudecek J., Hodek P., Anzenbacherova E., Anzenbacher P.:
    Structural analysis of cytochromes P450 shows differences in flexibility of heme 2- and 4-vinyls.
    Biochim Biophys Acta 1770, 413-419 (2007)
  21. Otyepka M, Skopalik J., Anzenbacherova E., Anzenbacher P.:
    What common structural features and variations of mammalian P450s are known to date?
    Biochim Biophys Acta 1770, 376-389 (2007)
  22. Lewis D.F., Lake B.G., Ito Y., Anzenbacher P.:
    Quantitative structure-activity relationships (QSARs) within cytochromes P450 2B (CYP2B) subfamily enzymes: the importance of lipophilicity for binding and metabolism.
    Drug Metabol Drug Interact. 2006;21(3-4):213-31
  23. Jančová P, Anzenbacherová E, Papoušková B, Lemr K, Lužná P, Veinlichová A, Anzenbacher P, Šimánek V:
    Silybin is metabolized by cytochrome P450 2C8 in vitro.
    Drug Metab Dispos 2007, Nov;35(11):2035-9 IF 4.015
  24. Svecova L, Vrzal R, Burysek L, Anzenbacherova E, Cerveny L, Grim J, Trejtnar F, Kunes J, Pour M, Staud F, Anzenbacher P, Dvorak Z, Pavek P.:
    Azole antimycotics differentially affect rifampicin-induced Pregnane X Receptor (PXR)-mediated CYP3A4 gene expression.
    Drug Metab Dispos. 2007 Nov 12; [Epub ahead of print] 2/2008 IF 3.64
  25. Nekvindová J, Anzenbacher P.:
    Interactions of food and dietary supplements with drug metabolising cytochrome P450 enzymes.
    Ceska Slov Farm. 2007 Jul;56(4):165-73.
  26. Anzenbacherová E, Anzenbacher P, Zídek Z, Buchar E, Kmoníčková E, Potměšil P, Nekvindová J, Veinlichová A, Holý A.:
    In vivo study of the effect of antiviral acyclic nucleotide phosphonate (R) - 9 - [2 -(phosphonomethoxy)propyl]adenine (PMPA, tenofovir) and its prodrug tenofovir disoproxil fumarate on rat microsomal cytochrome P450.
    Physiol Res. 2007 Oct 11; [Epub ahead of print] Printed version 5/2008 IF 2.09
  27. Orolin J, Vecera R, Jung D, Meyer UA, Skottová N, Anzenbacher P.:
    Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha.
    Xenobiotica. 2007 Jul;37(7):725-35. IF 1.613
  28. Vecera R, Klejdus B, Kosina P, Orolin J, Stiborová M, Smrcek S, Vicar J, Dvorák Z, Ulrichová J, Kubán V, Anzenbacher P, Simánek V.:
    Disposition of sanguinarine in the rat.
    Xenobiotica. 2007 May;37(5):549-58. IF 1.613
  29. Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, Pavek P.:
    Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways.
    Drug Metab Dispos. 2007 Jul; 35(7):1032-41. IF 3.64
  30. Masek V, Machova M, Anzenbacherova E, Brabec V, Anzenbacher V.:
    On the possible interaction of platinum chemotherapeutics with human liver microsomal cytochromes P450.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007, 151 (S1) 51-52.
  31. Matal J, Anzenbacherova E, Veinlichova A, Nobilis M, Anzenbacher P.:
    Interaction of nabumetone with cytochromes P450 in vitro: comparison of the man and pig.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007, 151 (S1) 53-54.

Reviews

  1. Anzenbacher P., Anzenbacherová E.:
    Cytochromes P450 and metabolism of xenobiotics.
    CMLS, Cell. Mol. Life Sci. 58, 737-747 ( 2001) (4,54)
  2. Anzenbacher P.:
    Úvod do farmakogenetiky.
    Klin. farmakol. a farmacie 16 (1-2), 7-9 (2002)
  3. Zuber R., Anzenbacherová E., Anzenbacher P.:
    Cytochromes P450 and experimental models of drug metabolism.
    J. Cell. Mol. Med. 6 (2), 189-198 (2002)
  4. Anzenbacher P., Anzenbacherová E.:
    Cytochromes P450: Review of their basic principles.
    Proc. Indian Natl. Science Acad. B 69 2003
  5. Anzenbacher P., Anzenbacherová E.: Cytochromes P450:
    How to study their structure and function and which animal model to choose.
    Nova Acta Leopoldina NF 87: 11-20 (2003)

Other

  1. Scheffield presentation (Sheffield_2006c.pdf)

INTRODUCTION |  HISTORY |  PROJECTS |  PUBLICATIONS |  PERSONAL |  COLLABORATION

Designed by G-SOFT © 2005